CSL Limited CMXHF Stock Profile

Description: CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Keywords: Disorders Influenza Neurological Disorders Blood Hereditary Angioedema Angioedema Blood Plasma Antitrypsin Deficiency Complement Deficiency Csl Behring Csl Limited Behring Non Plasma Biotherapeutic Products Biopharmaceutical And Allied Biopharmaceutical And Allied Products Bleeding Disorders Csl Treatment Of Immunodeficiency

Home Page: www.csl.com.au

655 Elizabeth Street
Melbourne, VIC 3000
Australia
Phone: 61 3 9389 1911

Officers

Name	Title
Dr. Paul F. McKenzie Ph.D.	MD, CEO & Executive Director
Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI	Interim Executive Vice President of CSL Behring
Mr. Andy Schmeltz	Executive Vice President of CSL Behring Business Unit (Leave of Absence)
Mr. John A. G. Levy CPA	Interim Chief Financial Officer
Chris Cooper	Head of Investor Relations
Mr. Gregory Boss B.S., BS(Hons), J.D.	Executive VP of Legal & General Counsel
Ms. Roanne Parry	Chief Human Resources Officer
Dr. Andrew D. Nash BSc (Hons), GAICD, Ph.D.	Senior Vice President of Research
Dr. William Mezzanotte M.D., M.P.H.	Executive VP & Head of Research and Development
Mr. Mark Hill B.A., M.B.A.	Chief Digital Information Officer & Executive VP

Exchange: PINK

Country: US : United States of America

Currency: US Dollar ($)

GIC Sector:	Health Care
GIC Group:	Pharmaceuticals, Biotechnology & Life Sciences
GIC Industry:	Biotechnology
GIC Sub-Industry:	Biotechnology

Forward PE:	27.5482
Trailing PE:	31.5236
Price-to-Book MRQ:	5.0197
Price-to-Sales TTM:	5.889
IPO Date:
Fiscal Year End:	June
Full Time Employees:	32698

CSL Limited(CMXHF)